Advertisement

Aspergillus Meningitis Linked to Steroid Injections Sickens 14 — Physician’s First Watch

Medical News |
October 4, 2012

Aspergillus Meningitis Linked to Steroid Injections Sickens 14

Fourteen patients — 13 in Tennessee and 1 in North Carolina — have contracted fungal meningitis after receiving spinal steroid injections for back pain, the New York Times reports. Two of the patients have died.

Clinicians suspect that the steroid, preservative-free methylprednisolone acetate, was contaminated with the fungus Aspergillus, according to the Times. All patients received injections between July 30 and September 18, and with the incubation period lasting as long as 4 weeks, more cases may still be identified.

The steroid was prepared by one compounding pharmacy and has been recalled nationwide; the name of the pharmacy has not been made public.

Asked to comment, Paul Sax of Journal Watch HIV/AIDS Clinical Care said: "What makes this [outbreak] notable is both the severity and the rarity of the condition, Aspergillus meningitis. Needless to say, consultation with a specialist in infectious diseases would be highly recommended for any clinician encountering such a case."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement